Epigenomics AG
Kleine Präsidentenstraße 1
Berlin
D-10178
Germany
Tel: 49-30-24-34-5-0
Fax: +49-30-24-34-55-55
Website: http://www.epigenomics.com/
Email: contact@epigenomics.com
218 articles about Epigenomics AG
-
New Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AG
7/24/2023
New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer.
-
New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening
8/10/2020
Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard® every three years, albeit at a higher colonoscopy referral rate
-
Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
12/2/2019
Adherence rates and screening intervals recognized as decisive elements of successful screening strategies
-
New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
11/29/2019
Adherence rates and screening intervals recognized as decisive elements of successful screening strategies
-
Epigenomics AG Reports Financial Results for the First Nine Months 2019
11/19/2019
Epigenomics AG announced its financial results for the first nine months of 2019.
-
Epigenomics AG Highlights Operational Achievements and Reports Financial Results for First Six Months 2019
8/7/2019
Epigenomics AG announced the operational achievements plus financial results for the second quarter and the first half of 2019.
-
Epigenomics AG Receives MedTech Outlook‘s 2019 Top 10 In-Vitro Diagnostics Award
7/11/2019
Company recognized for its leadership in advancing blood-based tests to diagnose cancer
-
New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome
6/17/2019
Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies
-
Epigenomics AG to Participate in Raymond James Life Sciences and MedTech Conference in June
6/4/2019
Epigenomics AG announced that company management will be presenting at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019, at 1:50 pm / 7:50 pm and invites investors to participate by webcast.
-
Epi proColon® Receives the 2019 Excellence in Molecular Diagnostics Award
5/9/2019
Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer.
-
Epigenomics AG Reports 2019 First Quarter Financial Results
5/8/2019
Epigenomics AG announced the financial results for the first quarter of the FY 2019.
-
CMS accepts Epigenomics’ application for NCD review
5/3/2019
-
Epigenomics AG Reports Results for Financial Year 2018
3/27/2019
Epigenomics AG announced the financial results for the year ended December 31, 2018.
-
U.S. Representatives Payne and Marchant Introduce Bi-Partisan Colorectal Cancer Detection Bill
3/15/2019
Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests
-
BioChain Responds to Epigenomics' unilateral termination of license contract
3/12/2019
The termination of the contract by Epigenomics is not legally effective.
-
BioChain Responds to Epigenomics' Unilateral Termination of License Contract - March 12, 2019
3/12/2019
BioChain, a US-based company, said Epigenomics AG of Germany seriously violated the terms of an ongoing licensing contract by publicly announcing on March 6, 2019 the unilateral termination of BioChain’s licensing right of Septin9 marker in China.
-
Epigenomics AG Announces Positive Results from Microsimulation Model
1/7/2019
-
Epigenomics AG Announces Initiation of a Prospective Clinical Study for Liver Cancer Detection
12/20/2018
Epigenomics AG today announced the initiation of a multi-center validation and development study of its methylated cell free DNA biomarkers to aid in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.
-
Centers for Medicare & Medicaid Services issue official 2019 Clinical Lab Fee Schedule including Epi proColon®
12/19/2018
Epigenomics AG today announced that the Centers for Medicare & Medicaid Services (CMS) have issued its official 2019 Clinical Lab Fee Schedule (CLFS) on December 14, 2018, including the final reimbursement rate of $192 for Epi proColon®, the first and only FDA-approved blood test for colorectal cancer screening.
-
Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results
11/7/2018
Epigenomics AG today announced its financial results for the third quarter and the nine months 2018 ending September 30.